Fundraising Fox66 Nao
1 known investors
Find your way into 66 Nao
Sign up to see every warm intro you have to 66 Nao
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 66 Nao team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
脑动极光 (66nao) develops medical-grade digital therapeutics that combine brain science with AI to assess and treat cognitive impairment caused by vascular disease, neurodegenerative disease, psychiatric disorders, and childhood developmental deficits. It operates in China's cognitive disorder digital therapeutics market and states its core product was the first regulator-approved cognitive disorder digital therapeutic in China.
Founders & leadership
蔡
蔡龙军首席技术官兼首席运营官、代理首席执行官兼代理首席研发官 (CTO & COO, Acting CEO & Acting CRDO)
王
王俊杰首席财务官及联席公司秘书 (CFO & Joint Company Secretary)
赖
赖知远市场及运营副总裁 (VP of Marketing and Operations)
谭
谭铮董事会主席、执行董事兼首席战略官 (Chairman & Chief Strategy Officer)
Investors · 1
Frequently asked questions
- What does 66 Nao do?
- 脑动极光 (66nao) develops medical-grade digital therapeutics that combine brain science with AI to assess and treat cognitive impairment caused by vascular disease, neurodegenerative disease, psychiatric disorders, and childhood developmental deficits. It operates in China's cognitive disorder digital therapeutics market and states its core product was the first regulator-approved cognitive disorder digital therapeutic in China.
- Who are 66 Nao's investors?
- 66 Nao's investors include F-Prime Capital.